{"filing":{"accession_number":"0001628280-26-053832","cik":"0002036042","ticker":"SION","company_name":"Sionna Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"sion-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm"},"events":[{"id":25860,"run_id":23477,"accession_number":"0001628280-26-053832","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Sionna Therapeutics issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($21.9M), G\u0026A expenses ($10.6M), net loss ($29.9M), and cash position ($268.3M). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26792,"accession_number":"0001628280-26-053832","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Sionna Therapeutics issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($21.9M), G\u0026A expenses ($10.6M), net loss ($29.9M), and cash position ($268.3M). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:13.260520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26792,"accession_number":"0001628280-26-053832","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Sionna Therapeutics issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($21.9M), G\u0026A expenses ($10.6M), net loss ($29.9M), and cash position ($268.3M). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:13.260520+00:00","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-08-06"}]}